Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

08 Oct, 2019 ,
OncLiveTV
OncLiveTV
08 Oct, 2019 ,

Dr. Karivedu discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). In a phase I open-label, single-site dose-escalation trial (NCT02325401), investigators evaluated the combination of metformin and chemoradiation in patients with HNSCC. Results presented at the 2018 ASCO Annual Meeting showed an increase in overall survival (OS) with the combination. Specifically, at 2 years, overall survival increased to 90%, says Karivedu.